Department of Urology, Tottori University School of Medicine, Yonago, Japan.
BJU Int. 2010 Oct;106(8):1181-5. doi: 10.1111/j.1464-410X.2010.09243.x.
to evaluate the effects of phosphodiesterase-5 inhibitors (PDE5-i) on Leydig cell secretory function (LCSF).
in all, 75 men with oligoasthenospermia were treated daily for 12 weeks with either vardenafil (23 men, group A), sildenafil (25 men, group B) or l-carnitine (26 men, group C); a further group of 22 men with oligoasthenospermia (group D) received no treatment. Serum levels of insulin-like-3 peptide (INSL3) were evaluated before and after the end of the treatment in each of groups A, B and C, respectively. Serum INSL3 levels were measured in each participant of group D before and after the 12-week experimental period.
within group A and B, the peripheral serum mean INSL3 concentration, sperm concentration, percentage of motile spermatozoa, and percentage of morphologically normal spermatozoa were significantly greater after PDE5-i treatment than before.
we suggest that PDE5-i enhances LCSF, as the mean INSL3 concentration was significantly greater after PDE5-i administration than before, within groups A and B. This enhancement in LCSF might contribute to the increase in sperm concentration and sperm motility after administration of PDE5-i.
评估磷酸二酯酶-5 抑制剂（PDE5-i）对莱迪希细胞分泌功能（LCSF）的影响。
共 75 名少弱精子症患者，每日接受治疗 12 周，分别给予伐地那非（23 名患者，A 组）、西地那非（25 名患者，B 组）或左旋肉碱（26 名患者，C 组）治疗；另有 22 名少弱精子症患者（D 组）未接受治疗。分别在 A、B 和 C 组每位患者治疗前后评估血清胰岛素样-3 肽（INSL3）水平。在 D 组每位参与者治疗前后 12 周实验期间分别测量血清 INSL3 水平。
A 组和 B 组内，PDE5-i 治疗后外周血平均 INSL3 浓度、精子浓度、活动精子百分比和形态正常精子百分比均显著高于治疗前。
我们认为 PDE5-i 增强了 LCSF，因为 A 组和 B 组内，PDE5-i 治疗后平均 INSL3 浓度显著高于治疗前。这种 LCSF 的增强可能有助于 PDE5-i 治疗后精子浓度和精子活力的增加。
